Literature DB >> 6693024

Acute psychosis in a 45-year-old man with bipolar disorder and primary Epstein-Barr virus infection: a case report.

R F Klein, R Betts, R Horn, J L Sullivan.   

Abstract

A 45-year-old physician with bipolar disorder presented with an acute organic psychosis, fever, and hematologic and serologic findings of a primary Epstein-Barr virus infection. Pathogenesis was complicated by the history of discontinued lithium therapy prior to the psychosis. The patient recovered completely. Literature concerning psychosis and infectious mononucleosis is reviewed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693024     DOI: 10.1016/0163-8343(84)90053-7

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  5 in total

1.  [Coenaesthesia after infection with Varicella zoster virus. The psychodynamic meaning of suffering a children's disease at adult age].

Authors:  B R Brüggemann; W Machleidt
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

2.  Psychosocial and biological aspects of acute brief psychoses in three developing country sites.

Authors:  P Y Collins; N N Wig; R Day; V K Varma; S Malhotra; A K Misra; B Schanzer; E Susser
Journal:  Psychiatr Q       Date:  1996

Review 3.  Acute and transient psychotic disorders: comparison with schizophrenia.

Authors:  Savita Malhotra; Sameer Malhotra
Journal:  Curr Psychiatry Rep       Date:  2003-07       Impact factor: 5.285

4.  Acute and transient psychosis: A paradigmatic approach.

Authors:  Savita Malhotra
Journal:  Indian J Psychiatry       Date:  2007-10       Impact factor: 1.759

5.  Schizophrenia is Associated With an Aberrant Immune Response to Epstein-Barr Virus.

Authors:  Faith Dickerson; Lorraine Jones-Brando; Glen Ford; Giulio Genovese; Cassie Stallings; Andrea Origoni; Colm O'Dushlaine; Emily Katsafanas; Kevin Sweeney; Sunil Khushalani; Robert Yolken
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.